See
Genome Information for Mus musculus
Control or A2V+CD40 treated Prox1-proficient (AP) and Prox1-deficient (APP) tumors
Overall design: Tumors induced in Apcflox/flox;Tp53flox/flox;villin-CreERT2 (AP) or Apcflox/flox;Tp53flox/flox;Prox1flox/flox;villin-CreERT2 (APP) mice for two weeks. Mice were randomized and treated with PBS, control IgG, or A2V+CD40 for two weeks.
| Accession | PRJNA513202; GEO: GSE124716 |
| Data Type | Transcriptome or Gene expression |
| Scope | Multiisolate |
| Organism | Mus musculus[Taxonomy ID: 10090] Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus; Mus musculus |
| Publications | Ragusa S et al., "Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice.", J Clin Invest, 2020 Mar 2;130(3):1199-1216 |
| Submission | Registration date: 6-Jan-2019
Vascular and Tumor Biology Lab, Oncology, University of Lausanne |
| Relevance | Model Organism |
Project Data:
| Resource Name | Number
of Links |
|---|
| Sequence data |
| SRA Experiments | 19 |
| Publications |
| PubMed | 1 |
| PMC | 1 |
| Other datasets |
| BioSample | 19 |
| GEO DataSets | 1 |